(The following press release from Bayer was received by e-mail. It was not 
confirmed by the sender.) 
Not intended for U.S. media
Bayer HealthCare completes acquisition of Teva’s U.S. animal health
New product lines strengthen Bayer’s animal health business in the U.S. 
Leverkusen, January 4, 2013 - Bayer HealthCare announced today that it has
received the necessary regulatory approval from the Federal Trade
Commission to complete the acquisition of the U.S.-based animal health
business of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). As announced
in September 2012, Bayer will pay up to 145 million USD which includes an
upfront payment of 60 million USD plus a total of 85 million USD in
milestone payments, which are linked to the successful and timely
achievement of manufacturing and sales targets. The transaction includes a
manufacturing site in St. Joseph, Missouri and around 300 employees. 
"This acquisition fits nicely with our strategic goals. It allows us to
strengthen and broaden our range of animal care solutions in the US
market," said Dr. Joerg Reinhardt, Chief Executive Officer, Bayer
The new portfolio will include a strong anti-infectives franchise and will
enable Bayer to be present in all major therapeutic areas. The companion
animal products features a full line of dermatology products sold under the
DVM Pharmaceutical brand, including such products as Malaseb, HyLyt, Relief
and others. Further companion animal products include a broad line of
nutraceuticals encompassing joint and gastro-intestinal products including
the Synovi brands. Food animal products acquired from Teva include a wide
range of anti-infectives in addition to parasiticides, anti-inflammatory
brands and reproductive hormones. 
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields
of health care, agriculture and high-tech materials. Bayer HealthCare, a
subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one
of the world’s leading, innovative companies in the healthcare and medical
products industry and is based in Leverkusen, Germany. The company combines
the global activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec
31, 2011) and is represented in more than 100 countries. More information
Our online press service is just a click away: 
Find more information at
Follow us on Facebook: 
Forward-Looking Statements
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead
to material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those discussed in Bayer’s public reports
which are available on the Bayer website at The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments. 
Bayer Animal Health GmbH
Kathrin Statz, Tel. +49 2173 38-4019
This press release is available here: 
Yours BayNews Editorial Team 
Bayer AG
Building W11
51368 Leverkusen, Germany 
Further news releases you can find here: 
To ensure receipt, please add to your
address book or list of trusted senders. 
© Bayer AG, 51368 Leverkusen, Germany 
All rights reserved. The entire contents, including images, graphics,
animations etc., of this e-mail and the server
are copyrighted. 
Board of Management: Marijn Dekkers, Chairman of the Board | Werner
Baumann, Wolfgang Plischke, Richard Pott
Chairman of the Supervisory Board: Werner Wenning
Registered Office: Leverkusen | Local Court Cologne, HRB 48248
Press spacebar to pause and continue. Press esc to stop.